×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRBP – corbus pharmaceuticals holdings, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRBP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/9
07:09 am
crbp
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors [Yahoo! Finance]
Low
Report
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors [Yahoo! Finance]
12/9
07:00 am
crbp
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Low
Report
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
12/4
12:45 pm
crbp
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
12/3
07:18 am
crbp
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer [Yahoo! Finance]
High
Report
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer [Yahoo! Finance]
12/3
07:00 am
crbp
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
High
Report
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
12/2
08:06 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $35.00 price target on the stock.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $35.00 price target on the stock.
11/26
07:01 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
11/21
08:00 am
crbp
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Medium
Report
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/3
08:00 am
crbp
Form 8-K Corbus Pharmaceuticals For: Dec 03
High
Report
Form 8-K Corbus Pharmaceuticals For: Dec 03
11/15
04:37 pm
crbp
Form 8-K Corbus Pharmaceuticals For: Nov 15
Low
Report
Form 8-K Corbus Pharmaceuticals For: Nov 15
11/14
07:48 pm
crbp
Form SC 13G/A Corbus Pharmaceuticals Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SC 13G/A Corbus Pharmaceuticals Filed by: Point72 Asset Management, L.P.
11/14
06:41 pm
crbp
Form SC 13G Corbus Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Medium
Report
Form SC 13G Corbus Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
11/14
04:07 pm
crbp
Form SC 13G/A Corbus Pharmaceuticals Filed by: K2 HealthVentures Equity Trust LLC
Medium
Report
Form SC 13G/A Corbus Pharmaceuticals Filed by: K2 HealthVentures Equity Trust LLC
11/14
04:00 pm
crbp
Form SC 13G/A Corbus Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
Medium
Report
Form SC 13G/A Corbus Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
11/14
03:09 pm
crbp
Form SC 13G/A Corbus Pharmaceuticals Filed by: Cormorant Asset Management, LP
Low
Report
Form SC 13G/A Corbus Pharmaceuticals Filed by: Cormorant Asset Management, LP
11/12
02:35 pm
crbp
Form SC 13G/A Corbus Pharmaceuticals Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Corbus Pharmaceuticals Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form 10-K Corbus Pharmaceuticals For: Dec 31
23.8%
3/26 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) is now covered by analysts at Nomura. They set a "buy" rating and a $112.00 price target on the stock. 12.7%
3/12 Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q4 2019 Earnings Call Transcript [The Motley Fool] 11.8%
3/18 Form 4 Corbus Pharmaceuticals For: Mar 17 Filed by: Millian Craig Stuart 10.0%
3/9 Form 4 Corbus Pharmaceuticals For: Mar 06 Filed by: Moran Sean F. 9.6%
3/18 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.3%
4/9 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.7%
5/10 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock. 5.2%
3/28 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.0%
1/14 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 4.8%
3/26 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) is now covered by analysts at Nomura. They set a "buy" rating and a $112.00 price target on the stock. 12.7%
3/12 Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q4 2019 Earnings Call Transcript [The Motley Fool] 11.8%
3/18 Form 4 Corbus Pharmaceuticals For: Mar 17 Filed by: Millian Craig Stuart 10.0%
3/9 Form 4 Corbus Pharmaceuticals For: Mar 06 Filed by: Moran Sean F. 9.6%
3/18 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.3%
4/9 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.7%
5/10 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock. 5.2%
3/28 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.0%
1/14 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 4.8%
TOP News Decliners
12/9
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
-9.1%
5/9 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus 0.020 ActVsEst (0.450) - Miss -8.9%
8/8 Form 8-K Corbus Pharmaceuticals For: Aug 08 -8.7%
2/26 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.75 price target on the stock. -8.5%
11/7 Q3/2019 9/30/2019 EPS -0.320 ZacksConsensus -0.360 ActVsEst 0.040 - Beat -8.0%
3/12 Q4/2019 12/31/2019 EPS -0.410 ZacksConsensus -0.340 ActVsEst (0.070) - Miss -7.3%
3/10 Form 4 Corbus Pharmaceuticals For: Mar 06 Filed by: Salzmann Peter -6.8%
2/6 Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock -6.4%
8/13 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $7.00 price target on the stock. -6.2%
3/5 Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020 -6.1%
5/9 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus 0.020 ActVsEst (0.450) - Miss -8.9%
8/8 Form 8-K Corbus Pharmaceuticals For: Aug 08 -8.7%
2/26 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.75 price target on the stock. -8.5%
11/7 Q3/2019 9/30/2019 EPS -0.320 ZacksConsensus -0.360 ActVsEst 0.040 - Beat -8.0%
3/12 Q4/2019 12/31/2019 EPS -0.410 ZacksConsensus -0.340 ActVsEst (0.070) - Miss -7.3%
3/10 Form 4 Corbus Pharmaceuticals For: Mar 06 Filed by: Salzmann Peter -6.8%
2/6 Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock -6.4%
8/13 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $7.00 price target on the stock. -6.2%
3/5 Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020 -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: